Finder makes money from featured partners, but editorial opinions are our own.

How to buy Incyte Corporation (INCY) stocks in Canada

Learn how to easily invest in Incyte Corporation stocks.

Incyte Corporation

NASDAQ: INCY-USD

About 3 hours ago

$51.74

+$0.09 (+0.17%)

Incyte Corporation is a biotechnology business based in the US. Incyte Corporation shares (INCY.US) are listed on the NASDAQ and all prices are listed in US dollars. Its last market close was $51.65 – a decrease of 0.52% over the previous day. Incyte Corporation employs 2,524 staff and has a trailing 12-month revenue of around $3.7 billion.

How to buy shares in Incyte Corporation

Choose a platform. If you're a beginner, our stock trading platform picks below can help you choose.
Open your account. Provide your personal information and sign up.
Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
Search the platform for stock code: INCY in this case.
Research stocks. The platform should provide the latest information available.
Buy your stocks. Place a market order or limit order with your preferred number of shares. It's that simple.

The whole process can take as little as 15 minutes. You'll need a smartphone or computer, an internet connection, your passport or driving licence and a means of payment.

Go to site

Free trades for young investors

Easy-to-use platform
Low fees
Student and young investor discounts

Go to site

Low margin rates

Access to international stock exchanges
Low margin rates
Powerful research tools

Go to site

Low commissions

$50 in free trades
Low commissions
Easy-to-use app

Our selection of top picks is based on the same criteria as our annual Stock Trading Platform Awards. This is updated yearly to reflect changes in the market.

"Best for" picks are those we've evaluated to be best for specific product features or categories – you can read our full methodology here. If we show a "Promoted" pick, it's been chosen from among our commercial partners and is based on factors that include special features or offers, and the commission we receive.

This isn't an exhaustive list of all the trading platforms out there. What's best for you depends on your own investing strategy, budget and financial goals.

Is it a good time to buy Incyte Corporation stock?

Only you can make the decision on the time to leap... but here's some supporting information and analysis.

Use our graph to track the performance of INCY stocks over time.

Share price volatility

Over the last 12 months, Incyte Corporation's shares have ranged in value from as little as $50.27 up to $75.74. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Incyte Corporation's is 0.672. This would suggest that Incyte Corporation's shares are less volatile than average (for this exchange).

Historical closes compared with the last close of $51.65

1 week (2024-04-16)	-2.03%
1 month (2024-03-21)	-9.35%
3 months (2024-01-23)	-15.11%
6 months (2023-10-23)	-6.01%
1 year (2023-04-23)	-31.36%
3 years (2021-04-22)	-39.65%
5 years (2019-04-23)	-29.75%

The gauge below shows real-time ratings that are based on 26 popular indicators such as moving averages, for specific time periods. It's not a recommendation but is simply technical analysis that can form part of your research.

Finder might not agree with the analysis and we take no responsibility. We also give no representations or warranty on the accuracy or completeness of the information provided on this page.

Is Incyte Corporation under- or over-valued?

Valuing a stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of overall performance. However, analysts commonly use some key metrics to help gauge value. Check out the Incyte Corporation P/E ratio, PEG ratio and EBITDA

Incyte Corporation's current stock price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 20x. In other words, Incyte Corporation stocks trade at around 20x recent earnings.

That's comparable to, say, the trailing 12-month P/E ratio for the United States stock markets on average as of November 09, 2023 (20.44).

Incyte Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.6945. A PEG ratio below 1 can be interpreted as meaning the shares are not overvalued given the current rate of growth.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Incyte Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the stock prices of multiple high-growth companies.

Incyte Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $738.5 million ($1 billion CAD).

The EBITDA is a measure of a Incyte Corporation's overall financial performance and is widely used to measure a its profitability.

Frequently asked questions

Incyte Corporation's shares were split on a 2:1 basis on 31 August 2000. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Incyte Corporation shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Incyte Corporation shares which in turn could have impacted Incyte Corporation's share price.
It's as easy to sell Incyte Corporation as it is to buy! Here's how to sell Incyte Corporation stocks that you already own.
1. Open your investment app. If you've got one with desktop access, you can log in online
2. Go to your portfolio. This should be in the main menu
3. Find your shares. You may be able to search your portfolio
4. Choose how many you'd like to sell. You'll be able to review the price and see how much you'll receive
5. Sell your Incyte Corporation shares. Your investment platform will let you know when your shares are sold

Incyte Corporation financials

Revenue TTM	$3.7 billion
Operating margin TTM	20.03%
Gross profit TTM	$1.6 billion
Return on assets TTM	6.46%
Return on equity TTM	12.5%
Profit margin	16.17%
Book value	$23.14
Market capitalisation	$11.9 billion

TTM: trailing 12 months

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.